Skip To Main Content
Jeff Craven on Muck Rack

Jeff Craven

As seen in: Flipboard, Medscape, Medscape Noticias Médicas, Medscape PT, The Philadelphia Inquirer, Healio Cardiac/Vascular Intervention, JD Supra, Internal Medicine News, MDedge Dermatology, MDedge Hematology and Oncology and
I help medical publishers, news sites, and businesses create outstanding print and web content. Used to have 300 followers, now I don't. @jeffbcraven@mas.to
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeff

Contact Jeff, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves

|
By Jeff Craven
| Regulatory Affairs Professionals Society
Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Open in Who Shared Issue with article?

Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again

|
By Jeff Craven
| Regulatory Affairs Professionals Society
Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Open in Who Shared Issue with article?

Experts discusses need to modernize evidentiary models in rare diseases

|
By Jeff Craven
| Regulatory Affairs Professionals Society
Experts discusses need to modernize evidentiary models in rare diseases Source: Ferdous Al-Faruque Using the US Food and Drug Administration’s (FDA) plausible mechanism framework to allow for greater use of causal inference may help with evidence generation for rare diseases, according to a recent paper published in The Journal of Clinical Investigation.
Open in Who Shared Issue with article?
See all 510 licensed articles (518 Total)